ChromaDex, Inc. on 2 November reported net sales off 1% to $17.1m, including $14.6m revenues from its Tru Niagen nicotinamide riboside supplement, but trimmed its net loss to less than $1m in its latest quarter.
The decline in third-quarter revenues primarily was attributable to lower business-to-business sales of Tru Niagen as distributors continue experiencing COVID-19 headwinds and other macroeconomic factors paired and to lower demand for research and development services
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?